

Discovery of hit and lead compounds based on oral IP6 kinase inhibition to treat obesity

Korea Advanced Institute of Science & Technology (KAIST)



METABOLIC	Hit
Product Type	Chemical product
Indication	Obesity
Target	IP6 kinase
MoA(Mechanism of Action)	Inhibition of IP6 kinase → Decreased production of 5-IP7 → Increased energy expenditure in adipose tissue
Competitiveness	Since there is no approved drug for targeting IP6 kinase, it is highly expected that the success of current project will lead to first-in-class drugs. More importantly, targeting adipose tissue metabolism approach can have multiple benefits over current appetite-controlling drugs.
Development Stage	Hit
Route of Administration	Oral administration